Title
Description description description. Description description description. Description description description.
As a parent, you have to speak up for your child. That means talking to the doctor about why TASIGNA® (nilotinib) capsules may be the right option to treat your child’s Philadelphia chromosome–positive chronic myeloid leukemia.
It is not known if TASIGNA is safe and effective in children younger than 1 year of age with newly diagnosed, resistant, or intolerant Ph+ CML in chronic phase.
The long-term effects of treating children with TASIGNA for a long period of time are not known.
Your child’s doctor will determine the proper dose of TASIGNA based on your child’s body weight and height.
In a clinical study of 25 children whose first treatment of Ph+ CML-CP was TASIGNA, nearly 7 out of 10 children (17 of 25 patients or 68%) achieved a major molecular response (MMR) by 24 cycles (28 days per cycle or 672 days, so under 2 years).
In a clinical study of 33 children who couldn’t tolerate or no longer benefited from GLEEVEC® (imatinib mesylate) or dasatinib who were switched to TASIGNA, nearly 6 out of 10 children (19 of 33 patients or 57%) achieved a MMR by 24 cycles (28 days per cycle or 672 days, so under 2 years).
Whether your child is newly diagnosed or is currently taking another medication to treat the disease, make yourself heard—and speak with your child’s doctor about TASIGNA.
In clinical trials with TASIGNA, the most common side effects in children included:
Be sure to review information about the serious and most common side effects of TASIGNA. Learn more
Use of website is governed by the Terms of Use and Privacy Policy.
Copyright © 2022 Novartis Pharmaceuticals Corporation. All rights reserved.
You are now leaving the Novartis site and moving to an external website independently operated and not managed by Novartis Pharmaceuticals Corporation. Novartis assumes no responsibility for the site. If you do not wish to leave this site, click Cancel or click OK to continue.
